After Selection as a NIP, Sales of Prevenar 13 and Synflorix Had a Significant Increase
After Pneumococcal vaccine was selected as a NIP (National Immunization Program) this May, Prevenar 13 of Pfizer and Synflorix of GSK have increased their sales as expected. However, Synflorix has attracted more attention as its market share has increased by 0.5%.
Looking at the market share aft...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
